See more : Sierra Lake Acquisition Corp. (SIERU) Income Statement Analysis – Financial Results
Complete financial analysis of Purple Biotech Ltd. (PPBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Purple Biotech Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Australian Agricultural Company Limited (ASAGF) Income Statement Analysis – Financial Results
- Jacobson Pharma Corporation Limited (2633.HK) Income Statement Analysis – Financial Results
- Curaleaf Holdings, Inc. (CURLF) Income Statement Analysis – Financial Results
- Canal Capital Corporation (COWP) Income Statement Analysis – Financial Results
- Mitsuboshi Co., Ltd. (5820.T) Income Statement Analysis – Financial Results
Purple Biotech Ltd. (PPBT)
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | -910.00K | -320.00K | 1.00M | 1.00M | 1.00M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 196.00K | 201.00K | 231.00K | 235.00K | 80.00 | 0.00 | 4.00K | 2.00K | 999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -196.00K | -1.11M | -551.00K | 765.00K | 999.92K | 1.00M | 897.00K | -2.00K | -999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 122.09% | 172.19% | 76.50% | 99.99% | 100.00% | 99.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.03M | 16.32M | 11.83M | 7.49M | 2.67M | 5.27M | 4.64M | 4.18M | 2.56M | 3.19M | 109.00K | 94.00 |
| General & Administrative | 0.00 | 5.96M | 5.82M | 6.07M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Selling & Marketing | 0.00 | 321.00K | 286.00K | 235.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.04M | 6.28M | 6.11M | 6.31M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Other Expenses | -44.54M | 0.00 | 0.00 | -15.66M | -216.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -22.47M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Cost & Expenses | -22.27M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Interest Income | 474.00K | 969.00K | 320.00K | 254.00K | 151.00K | 93.00K | 106.00K | 138.00K | 94.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.18M | 126.00K | 212.00K | 61.00K | 181.00K | 576.00K | 26.00K | 6.00K | 3.00K | 21.00K | 48.00K | 0.00 |
| Depreciation & Amortization | 199.00K | 201.00K | 231.00K | 235.00K | 178.00K | 7.00K | 4.00K | 2.00K | 1.00K | -50.00K | -27.00K | 957.22 |
| EBITDA | -22.23M | -21.49M | -17.52M | -28.41M | -6.14M | -5.55M | -12.88M | -7.04M | -4.20M | -5.43M | -2.58M | 255.22 |
| EBITDA Ratio | 0.00% | 2,355.27% | 5,432.19% | -2,796.00% | -763.80% | -772.60% | -1,323.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | -7.83M | -12.25M | -7.18M | -4.07M | -5.18M | -2.55M | -702.00 |
| Operating Income Ratio | 0.00% | 2,483.85% | 5,604.38% | 1,261.20% | -715.60% | -782.60% | -1,359.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -42.25M | -43.52M | 108.00K | -15.46M | 1.48M | 2.26M | -947.00K | -4.94M | -133.00K | -71.00K | -75.00K | -1.00 |
| Income Before Tax | -19.98M | -21.76M | -17.83M | -28.07M | -5.89M | -5.57M | -13.01M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Income Before Tax Ratio | 0.00% | 2,391.21% | 5,570.63% | -2,807.40% | -589.30% | -556.90% | -1,443.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -935.00K | 637.00K | -15.67M | 216.00K | -2.63M | 26.00K | 4.94M | 133.00K | 50.00K | 27.00K | 0.00 |
| Net Income | -19.88M | -20.83M | -18.46M | -12.41M | -6.11M | -5.20M | -12.27M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Net Income Ratio | 0.00% | 2,288.46% | 5,769.69% | -1,240.50% | -610.90% | -520.00% | -1,362.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.49 |
| EPS Diluted | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.41 |
| Weighted Avg Shares Out | 221.33M | 184.82M | 178.00M | 172.11M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.00 |
| Weighted Avg Shares Out (Dil) | 221.33M | 184.82M | 178.00M | 172.11M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.55 |
What Makes Purple Biotech (PPBT) a New Buy Stock
Purple Biotech (PPBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology ( ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in...
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule
REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced that on July 24, 2024,...
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its virtual...
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its...
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered...
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today reported additional positive interim data from...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
REHOVOT, Israel, June 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment and immune system to overcome tumor immune evasion...
Purple Biotech Reports First Quarter 2024 Financial Results
CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024 CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation...
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study
Source: https://incomestatements.info
Category: Stock Reports